Harsha Allu, MD
Hospitalist · Charlotte, NCNPI 1417159518
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 448 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,683 and has fallen 52.4% since, to $802 in 2025. Among hospitalist clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 448 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$1K
- Boehringer Ingelheim$913
- Novartis$720
- Gilead$713
- Pfizer$642
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,568100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 57 | $1,080 |
| Johnson & Johnson | 57 | $1,067 |
| Boehringer Ingelheim | 37 | $913 |
| Novartis | 36 | $720 |
| Gilead | 27 | $713 |
| Pfizer | 44 | $642 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 26 | $514 |
| Alnylam Pharmaceuticals Inc. | 17 | $394 |
| AstraZeneca(2 entities) | 22 | $343 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $327 |
| Merck | 14 | $302 |
| Electromed, Inc. | 19 | $260 |
| Boston Scientific | 13 | $226 |
| Paratek Pharmaceuticals, Inc. | 13 | $205 |
| E.r. Squibb & Sons, L.L.C. | 12 | $201 |
| Melinta Therapeutics, LLC | 8 | $127 |
| Scpharmaceuticals Inc. | 3 | $117 |
| Philips North America LLC | 5 | $88 |
| Sunovion Pharmaceuticals Inc. | 6 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| Kestra Medical Technology Services, Inc. | 2 | $38 |
| Inari Medical, Inc. | 1 | $37 |
| Tactile Systems Technology Inc | 2 | $34 |
| Abbott | 1 | $24 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| CMP Pharma, Inc. | 1 | $13 |
How this compares
$8,568 in reported general payments places this provider in the 95th percentile of 879 hospitalist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Furosemide | 11 | $36 |
| Pantoprazole Sodium | 15 | $32 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in Charlotte
- Javad MonzavifarCharlotte$12K
- Bikki GautamCharlotte$12K
- Jorge PaulinoCharlotte$12K
- Emmett StewardCharlotte$11K
- Tabita MorrisCharlotte$11K
- Samyak ManandharCharlotte$11K
- David HendersonCharlotte$10K
- Amsalu BizunehCharlotte$9K
- Jehana JamesCharlotte$8K
- Tyler DicksonCharlotte$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.